The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
Report Scope
This report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors. The geographical scope of this study is global. Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors. The report discusses market shares of kinase inhibitors based on type, application and geography.
Based on type, the market is segmented into tyrosine kinase inhibitors and serine/threonine kinase inhibitors. Tyrosine kinase inhibitors are further segmented into receptor and non-receptor tyrosine kinase inhibitors.
Based on application, the market is segmented into antineoplastic agents, age-related molecular degeneration (AMD) and immunosuppressants.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. Analyses of the markets of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India are covered in regional segments. For market estimates, data has been provided for the year 2020 as the base year, with forecasts for 2021 through 2026. Estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
The Report Includes
- 27 data tables and 28 additional tables
- An overview of the global markets for kinase inhibitors
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020 estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast and technological advancements within the industry
- Information on enzyme inhibitors, kinase inhibitors and classification by types of amino acid & phosphorylation
- Analysis of pipeline products and kinase inhibitors related patents, and comparative description of multiple single kinase inhibitors versus single multi-kinase inhibitors in terms of efficacy, resistance and pharmacokinetics
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major players, including Pfizer, Novartis AG, AstraZeneca, Bayer AG, Eisai Co. Ltd. and Johnson & Johnson
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Definitions
- Enzymes
- Coenzymes
- Enzyme Inhibitors
- Active Site
- Enzyme Inhibitors
- Why Enzyme Inhibition?
- Use of Enzyme Inhibitors
- Mechanism of Enzyme Inhibition
- Types of Enzyme Inhibitors
- Classification of Enzyme Inhibitors
- Kinase Inhibitors
- History of Protein Kinases
- Type of Kinase Inhibitors
- Classification by Types of Amino Acid Phosphorylation
- Classification by Site of Action
- Market Dynamics
- Drivers
- Market Restraints
- Opportunity
Chapter 4 Covid Impact on Market
- Overview
- Short-Term Impact on Pharmaceutical Industry
- Long-Term Impact
- Current Outlook
- COVID-19 Impact on Cancer Care
Chapter 5 Regulatory Scenario
- Overview
- Market Leaders and Their Products for Kinase Inhibitors
Chapter 6 Market Breakdown by Type
- Introduction
- Tyrosine Kinase Inhibitors
- Market Size and Forecast
- Market Analysis
- Serine/Threonine Kinase Inhibitors
- mTOR Kinase Inhibitors
- B-Raf
- RHO Kinase Inhibitors
- Cyclin-Dependent Kinase Inhibitors
- Aurora Kinase Inhibitors
- MAP/MEK Kinase Inhibitors
- JNK Inhibitors
- Protein Kinase C Inhibitors
- PI3K Inhibitors
- Market Size and Forecast
- Market Analysis
Chapter 7 Market Breakdown by Application
- Introduction
- Antineoplastic Agents
- Market Size and Forecast
- Market Analysis
- Age-related Macular Degeneration (AMD)
- Market Size and Forecast
- Market Analysis
- Immunosuppressant
- Market Size and Forecast
- Market Analysis
Chapter 8 Market Breakdown by Region
- Introduction
- North America
- Market Analysis
- U.S.
- Canada
- Europe
- Market Analysis
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Market Analysis
- China
- Japan
- India
- Rest of Asia-Pacific
- Rest of the World
- Market Size and Forecast
- Market Analysis
Chapter 9 Industry Developments
- Company Share Analysis
- Pipeline Analysis
- Patent Analysis
- Current Scenario
- Cancer and Kinase Inhibitors
- Multiple Single Kinase Inhibitors Vs. Single Multi-kinase Inhibitors
- Efficacy
- Resistance
- Pharmacokinetics
- Selectivity
- Tumor Microenvironment
- Toxicity
- Future Directions
Chapter 10 Company Profiles
- Leading Companies
- Astrazeneca
- Bayer Ag
- Boehringer Ingelheim International Gmbh
- Bristol-Myers Squibb
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Novartis Ag
- Pfizer
- Other Manufacturers
- Astellas Pharma Inc.
- Aveo Pharmaceuticals, Inc.
- Exelixis Inc.
- Merck Kgaa
- Sanofi
- Takeda Pharmaceutical Co., Ltd.
Chapter 11 Appendix A: Abbreviations and Acronyms
List of Tables
Summary Table A: Global Market for Kinase Inhibitors, by Type, Through 2026
Summary Table B: Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2026
Table 1: Classification of Enzyme Inhibitors
Table 2: History of Protein Kinases
Table 3: ATP-Competitive and Non-Competitive Inhibitors
Table 4: Types of Serine/Threonine Kinase Inhibitors
Table 5: Types of Receptor Tyrosine Kinase Inhibitors
Table 6: Types of Non-Receptor Tyrosine Kinase Inhibitors
Table 7: Classification of Kinase Inhibitors by Site of Action
Table 8: Patent Expiration Dates of Kinase Inhibitors
Table 9: Coronavirus Reported Cases and Deaths, by Country, May 2021
Table 10: FDA-Approved Kinase Inhibitors, 2001-2021
Table 11: FDA-approved Kinase Inhibitors and Their Drug Targets
Table 12: EMA-approved Kinase Inhibitors, 2001-2020
Table 13: Safety Alerts and Warnings for Kinase Inhibitors
Table 14: Leading Manufacturers and Suppliers of Receptor Tyrosine Kinase Inhibitors
Table 15: Leading Manufacturers and Suppliers of Non-Receptor Tyrosine Kinase Inhibitors
Table 16: Leading Manufacturers and Suppliers of Serine/Threonine Tyrosine Kinase Inhibitors
Table 17: Global Market for Kinase Inhibitors, by Type, Through 2026
Table 18: Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2026
Table 19: Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2026
Table 20: Global Market for Serine/Threonine Kinase Inhibitors, by Region, Through 2026
Table 21: Global Market for Kinase Inhibitors, by Application, Through 2026
Table 22: Global Market for Kinase Inhibitors Used as Antineoplastic Agents, by Region, Through 2026
Table 23: Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, by Region, Through 2026
Table 24: Global Market for Kinase Inhibitors Used as Immunosuppressants, by Region, Through 2026
Table 25: Global Market for Kinase Inhibitors, by Region, Through 2026
Table 26: North American Market for Kinase Inhibitors, by Type, Through 2026
Table 27: North American Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 28: North American Market for Kinase Inhibitors, by Application, Through 2026
Table 29: North American Market for Kinase Inhibitors, by Country, Through 2026
Table 30: European Market for Kinase Inhibitors, by Type, Through 2026
Table 31: European Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 32: European Market for Kinase Inhibitors, by Application, Through 2026
Table 33: European Market for Kinase Inhibitors, by Country, Through 2026
Table 34: Asia-Pacific Market for Kinase Inhibitors, by Type, Through 2026
Table 35: Asia-Pacific Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 36: Asia-Pacific Market for Kinase Inhibitors, by Application, Through 2026
Table 37: Asia-Pacific Market for Kinase Inhibitors, by Country, Through 2026
Table 38: ROW Market for Kinase Inhibitors, by Type, Through 2026
Table 39: ROW Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 40: ROW Market for Kinase Inhibitors, by Application, Through 2026
Table 41: Revenue from Kinase Inhibitors, 2019-2020
Table 42: Ongoing Clinical Trials of Various Kinase Inhibitors
Table 43: Patents Filed for Kinase Inhibitors
Table 44: AstraZeneca: Kinase Inhibitors Drugs Product Portfolio
Table 45: Bayer AG: Kinase Inhibitors Drugs Product Portfolio
Table 46: Boehringer Ingelheim: Kinase Inhibitors Drugs Product Portfolio
Table 47: Bristol-Myers Squibb: Kinase Inhibitors Drugs Product Portfolio
Table 48: Eisai Co.: Kinase Inhibitors Drugs Product Portfolio
Table 49: F. Hoffmann-La Roche: Kinase Inhibitor Drugs Product Portfolio
Table 50: Johnson & Johnson: Kinase Inhibitors Drugs Product Portfolio
Table 51: Novartis AG: Kinase Inhibitor Drugs Product Portfolio
Table 52: Pfizer: Kinase Inhibitor Drugs Product Portfolio
Table 53: Abbreviations Used in This Report
List of Figures
Summary Figure A: Global Market Shares of Kinase Inhibitors, by Application, 2020
Summary Figure B: Global Market for Kinase Inhibitors, by Region, 2019-2026
Figure 1: Estimated Numbers of New Cancer Cases in Women, 2020
Figure 2: Estimated Numbers of New Cancer Cases in Men, 2020
Figure 3: National Cancer Institute Research Funding, 2012-2019
Figure 4: Impact of COVID-19 on Pharmaceutical Industry
Figure 5: Global Market Shares of Kinase Inhibitors, by Type, 2020
Figure 6: Global Market for Tyrosine Kinase Inhibitors, 2020-2026
Figure 7: Global Market for Tyrosine Kinase Inhibitors, by Region, 2019-2026
Figure 8: Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2020
Figure 9: Global Market for Serine/Threonine Kinase Inhibitors, 2020-2026
Figure 10: Global Market for Serine/Threonine Kinase Inhibitors, by Region, 2019-2026
Figure 11: Global Market Shares of Kinase Inhibitors, by Application, 2020
Figure 12: Global Market for Kinase Inhibitors Used as Antineoplastic Agents, 2020-2026
Figure 13: Global Market for Kinase Inhibitors Used as Antineoplastic Agents, by Region, 2019-2026
Figure 14: Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, 2020-2026
Figure 15: Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, by Region, 2019-2026
Figure 16: Global Market for Kinase Inhibitors Used as Immunosuppressants, 2020-2026
Figure 17: Global Market for Kinase Inhibitors Used as Immunosuppressants, by Region, 2019-2026
Figure 18: Global Market Shares of Kinase Inhibitors, by Region, 2020
Figure 19: North American Market Shares of Kinase Inhibitors, by Type, 2020
Figure 20: North American Market Shares of Kinase Inhibitors, by Application, 2020
Figure 21: North American Market Shares of Kinase Inhibitors, by Country, 2020
Figure 22: U.S. Market for Kinase Inhibitors, 2020-2026
Figure 23: Canadian Market for Kinase Inhibitors, 2020-2026
Figure 24: European Market Shares of Kinase Inhibitors, by Type, 2020
Figure 25: European Market Shares of Kinase Inhibitors, by Application, 2020
Figure 26: European Market Shares of Kinase Inhibitors, by Country, 2020
Figure 27: German Market for Kinase Inhibitors, 2020-2026
Figure 28: U.K. Market for Kinase Inhibitors, 2020-2026
Figure 29: French Market for Kinase Inhibitors, 2020-2026
Figure 30: Italian Market for Kinase Inhibitors, 2020-2026
Figure 31: Spanish Market for Kinase Inhibitors, 2020-2026
Figure 32: Rest of Europe Market for Kinase Inhibitors, 2020-2026
Figure 33: Asia-Pacific Market Shares of Kinase Inhibitors, by Type, 2020
Figure 34: Asia-Pacific Market Shares of Kinase Inhibitors, by Application, 2020
Figure 35: Asia-Pacific Market Shares of Kinase Inhibitors, by Country, 2020
Figure 36: Chinese Market for Kinase Inhibitors, 2020-2026
Figure 37: Japanese Market for Kinase Inhibitors, 2020-2026
Figure 38: Indian Market for Kinase Inhibitors, 2020-2026
Figure 39: Rest of Asia-Pacific Market for Kinase Inhibitors, 2020-2026
Figure 40: ROW Market Shares of Kinase Inhibitors, by Type, 2020
Figure 41: ROW Market Shares of Kinase Inhibitors, by Application, 2020
Figure 42: Global Market Share Analysis of Kinase Inhibitor, by Company, 2020
Figure 43: Clinical Trial Phases of Various Kinase Inhibitors, 2020
Figure 44: AstraZeneca: Annual Revenue, 2017-2020
Figure 45: Bayer AG: Annual Revenue, 2017-2020
Figure 46: Boehringer Ingelheim: Annual Revenue, 2017-2020
Figure 47: Bristol-Myers Squibb: Annual Revenue, 2017-2020
Figure 48: Eisai Co. Ltd.: Annual Revenue, 2017-2019
Figure 49: F. Hoffmann-La Roche: Annual Revenue, 2017-2020
Figure 50: Johnson & Johnson: Annual Revenue, 2017-2020
Figure 51: Novartis AG: Financial Performance, 2017-2020
Figure 52: Pfizer: Annual Revenue,2017-2020
Samples
LOADING...
Executive Summary
In 1992, biochemists Edmond H. Fischer and Edwin G. Krebs were awarded the Nobel Prize in Physiology or Medicine for their research of how reversible phosphorylation works as a switch to activate proteins and regulate various other cellular processes. Their findings offered momentum to the popularity of reversible phosphorylation of proteins as central to the regulation of most aspects of cell function and cell physiology. An increasing number of human diseases have been shown to involve mutations, overexpression, genetic association or malfunctioning of protein kinases and phosphatases and their regulators and effectors.
The dynamic field of cancer R&D is allowing an enhancement to the specialization in kinases, which play a crucial role as mediators in many sorts of cancer and other diseases, and also demonstrate a pivotal role in modulating diverse cellular activities.
The market for kinase inhibitor market is experiencing an increasing demand for a number of novel kinase inhibitors being utilized in human trials. The kinase inhibitor field is seeing a rise in the development of next-generation inhibitors that focus on cancers and other diseases, including inflammation. As the field of kinase inhibitors matures, market leaders are trying to answer questions regarding technologies and methods used or in reference to novel targets and therapeutic approaches concerning kinase inhibitors.
The growth of the global market is attributed to factors such as the growing prevalence of cancer and other chronic diseases, and strong investment in R&D activities by key market players. Pfizer and Novartis are the leaders in the kinase inhibitor market. Companies are investing in research to deal with issues such as resistance, selectivity vs. safety, developing lead compounds, integrating chemistry and biology into development, and utilizing the newest techniques, such as fragment- and structure-based design, to develop new products.
The presence of pharmaceutical giants in this region, a developed regulatory and healthcare infrastructure, and stronger intellectual property protection are favorable factors for the growth of the U.S. market for kinase inhibitors. The rising prevalence of many chronic diseases along with growing aging population also drives the market in the U.S. and Europe, particularly the U.K. However, the decision of the U.K. government to exit the E.U., aka Brexit, might prove a deterrent for investors in the U.K. market for enzyme inhibitors. The emerging markets, particularly the Asia-Pacific region, have shown growth potential in recent years. The rising affluence in these countries has brought a change in the lifestyles of the populations, which have resulted in increased incidences of diseases such as cancers and immunological disorders. Countries in Africa and other developing countries are still battling with some of the highest proportions of immune-mediated diseases. The need for affordable and innovative medicines is the growth driver for the kinase inhibitor market in the low- and middle-income developing countries of the emerging markets.
Companies Mentioned
- Astellas Pharma Inc.
- Astrazeneca
- Aveo Pharmaceuticals, Inc.
- Bayer Ag
- Boehringer Ingelheim International Gmbh
- Bristol-Myers Squibb
- Eisai Co. Ltd.
- Exelixis Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Merck Kgaa
- Novartis Ag
- Pfizer
- Sanofi
- Takeda Pharmaceutical Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 129 |
| Published | June 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 57.6 Billion |
| Forecasted Market Value ( USD | $ 79.2 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
